NDC product
Histanaz
NDC 29978-129 · Capital Pharmaceutical, LLC
Key facts
| Product NDC | 29978-129 |
|---|---|
| Proprietary name | Histanaz |
| Nonproprietary name | Pseudoephedrine HCL, Pyrilamine Maleate |
| Substances | PSEUDOEPHEDRINE HYDROCHLORIDE, PYRILAMINE MALEATE |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Capital Pharmaceutical, LLC |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M012 |
| Pharmacologic classes | Adrenergic alpha-Agonists [MoA], alpha-Adrenergic Agonist [EPC] |
| Marketing start | Sep 8, 2025 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: